Ji Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ji Luo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Huan Li
Human Disease Genes Key Laboratory of Sichuan Province and Institute of Laboratory Medicine Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital University of Electronic Science and Technology of China Chengdu China
1 shared publication - Jiao Chen
Department of pathology, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China
1 shared publication - Ling Zhong
University of Electronic Science and Technology of China 2 Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People’s Hospital Chengdu, China
1 shared publication - Ninghan Bd Gong
University of Electronic Science and Technology of China, Chengdu, Sichuan, China
1 shared publication - Qian Mm Xi
Department of Clinical and Experimental Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, School of medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China
1 shared publication - Shuai Bd Zheng
University of Electronic Science and Technology of China, Chengdu, Sichuan, China
1 shared publication
Latest Publications
- Open Access
- 26 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (4) , e36948
Acute undifferentiated leukemia with undifferentiated myeloid sarcoma: Case report and literature review
Background: With the advancement of diagnostic technology, true acute undifferentiated leukemia (AUL) is becoming more rare, and AUL with extramedullary sarcoma has not been reported. Case presentation: This article reports a case of AUL with extramedullary sarcoma. Flow cytometric analysis of the bone marrow and lymph nodes indicated that the tumor cells of both were of the same origin and mainly expressed stem cell markers and CD7, no myeloid-specific markers, T-lymphoblastic-related markers, and B-lymphoblastic-related markers. Although the priming regimen combined with azacitidine was ineffective, complete remission was achieved by switching to azacitidine combined with HIA (homoharringtonine, idarubicin plus Ara-C). Conclusion: To diagnosis de novo acute leukemia with extensive and comprehensive cellular immune maker detection is available and credible, the expression of a single relatively nonspecific myeloid antigen as a immune maker to detect AUL or AUL associated with sarcoma is precise and effective in our case, which patient was benefit from HIA regiment.
- 26 January 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (4) , e36948
Open AccessAcute undifferentiated leukemia with undifferentiated myeloid sarcoma: Case report and literature review
Background: With the advancement of diagnostic technology, true acute undifferentiated leukemia (AUL) is becoming more rare, and AUL with extramedullary sarcoma has not been reported. Case presentation: This article reports a case of AUL with extramedullary sarcoma. Flow cytometric analysis of the bone marrow and lymph nodes indicated that the tumor cells of both were of the same origin and mainly expressed stem cell markers and CD7, no myeloid-specific markers, T-lymphoblastic-related markers, and B-lymphoblastic-related markers. Although the priming regimen combined with azacitidine was ineffective, complete remission was achieved by switching to azacitidine combined with HIA (homoharringtonine, idarubicin plus Ara-C). Conclusion: To diagnosis de novo acute leukemia with extensive and comprehensive cellular immune maker detection is available and credible, the expression of a single relatively nonspecific myeloid antigen as a immune maker to detect AUL or AUL associated with sarcoma is precise and effective in our case, which patient was benefit from HIA regiment.